LivaNova PLC (NASDAQ:LIVN) has earned an average rating of “Hold” from the ten research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $78.17.
A number of equities analysts recently commented on the stock. Needham & Company LLC lifted their target price on shares of LivaNova to $93.00 and gave the stock a “buy” rating in a research report on Tuesday, November 21st. Canaccord Genuity reiterated a “hold” rating and issued a $76.00 target price on shares of LivaNova in a research report on Tuesday, December 5th. Piper Jaffray Companies reiterated a “buy” rating and issued a $85.00 target price on shares of LivaNova in a research report on Friday, November 3rd. BidaskClub cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 12th. Finally, Zacks Investment Research upgraded shares of LivaNova from a “hold” rating to a “buy” rating and set a $89.00 target price on the stock in a research report on Thursday, November 9th.
Shares of LivaNova (NASDAQ LIVN) opened at $79.15 on Tuesday. The company has a current ratio of 2.03, a quick ratio of 1.42 and a debt-to-equity ratio of 0.04. The firm has a market cap of $3,815.95, a price-to-earnings ratio of 67.65, a PEG ratio of 2.44 and a beta of 0.61. LivaNova has a 52-week low of $44.58 and a 52-week high of $88.56.
In other LivaNova news, Director Hugh M. Morrison sold 1,830 shares of the firm’s stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $88.00, for a total value of $161,040.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $74.58, for a total transaction of $74,580.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,830 shares of company stock worth $569,350. 0.28% of the stock is owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. grew its holdings in LivaNova by 9.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock worth $105,000 after acquiring an additional 153 shares during the last quarter. Arizona State Retirement System grew its holdings in LivaNova by 1.7% in the 2nd quarter. Arizona State Retirement System now owns 18,300 shares of the company’s stock worth $1,120,000 after acquiring an additional 300 shares during the last quarter. Thrivent Financial For Lutherans grew its holdings in LivaNova by 7.6% in the 2nd quarter. Thrivent Financial For Lutherans now owns 8,770 shares of the company’s stock worth $537,000 after acquiring an additional 620 shares during the last quarter. Riverhead Capital Management LLC grew its holdings in LivaNova by 76.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company’s stock worth $108,000 after acquiring an additional 763 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in LivaNova by 1.3% in the 3rd quarter. Rhumbline Advisers now owns 94,714 shares of the company’s stock worth $6,636,000 after acquiring an additional 1,189 shares during the last quarter. 86.00% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “LivaNova PLC (LIVN) Given Average Rating of “Hold” by Analysts” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/26/livanova-plc-livn-given-average-rating-of-hold-by-analysts.html.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.